FDA is advised to reject wider use of Amgen's Xgeva

02/8/2012 | Reuters

An expert panel urged the FDA not to approve Amgen's Xgeva for delaying the spread of prostate cancer to the bone, saying the drug's benefits do not outweigh the risk of developing osteonecrosis of the jaw. Xgeva provides a meaningful benefit, and is being tested against other cancers, including breast, lung and multiple myeloma, Amgen said. The FDA will issue a final ruling by April 26.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD